764 related articles for article (PubMed ID: 33822361)
21. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
22. The landscape of COVID-19 vaccination among healthcare workers at the first round of COVID-19 vaccination in China: willingness, acceptance and self-reported adverse effects.
Ye X; Ye W; Yu J; Gao Y; Ren Z; Chen L; Dong A; Yi Q; Zhan C; Lin Y; Wang Y; Huang S; Song P
Hum Vaccin Immunother; 2021 Dec; 17(12):4846-4856. PubMed ID: 34618663
[TBL] [Abstract][Full Text] [Related]
23. Reactogenicity among health care workers following a BNT162b2 or mRNA-1273 second dose after priming with a ChAdOx1 nCOV-19 vaccine.
Baldolli A; Fournier A; Verdon R; Michon J
Clin Microbiol Infect; 2022 Jun; 28(6):885.e1-885.e5. PubMed ID: 35182759
[TBL] [Abstract][Full Text] [Related]
24. Safety of an Inactivated SARS-CoV-2 Vaccine Among Healthcare Workers in Turkey: An Online Survey.
Baydar O; Özen Ş; Öztürk Şahin B; Köktürk N; Kitapçı MT
Balkan Med J; 2022 May; 39(3):193-198. PubMed ID: 35380034
[TBL] [Abstract][Full Text] [Related]
25. Acceptance of COVID-19 vaccine in Pakistan among health care workers.
Malik A; Malik J; Ishaq U
PLoS One; 2021; 16(9):e0257237. PubMed ID: 34525110
[TBL] [Abstract][Full Text] [Related]
26. Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial.
Wu S; Huang J; Zhang Z; Wu J; Zhang J; Hu H; Zhu T; Zhang J; Luo L; Fan P; Wang B; Chen C; Chen Y; Song X; Wang Y; Si W; Sun T; Wang X; Hou L; Chen W
Lancet Infect Dis; 2021 Dec; 21(12):1654-1664. PubMed ID: 34324836
[TBL] [Abstract][Full Text] [Related]
27. Effectiveness of mRNA-BNT162b2, mRNA-1273, and ChAdOx1 nCoV-19 vaccines against COVID-19 in healthcare workers: an observational study using surveillance data.
Paris C; Perrin S; Hamonic S; Bourget B; Roué C; Brassard O; Tadié E; Gicquel V; Bénézit F; Thibault V; Garlantézec R; Tattevin P
Clin Microbiol Infect; 2021 Nov; 27(11):1699.e5-1699.e8. PubMed ID: 34265462
[TBL] [Abstract][Full Text] [Related]
28. Early Safety Monitoring of COVID-19 Vaccines in Healthcare Workers.
Song JY; Cheong HJ; Kim SR; Lee SE; Kim SH; Noh JY; Yoon YK; Choi WS; Park DW; Sohn JW; Kim WJ; Kim MJ
J Korean Med Sci; 2021 Apr; 36(15):e110. PubMed ID: 33876589
[TBL] [Abstract][Full Text] [Related]
29. Self-Reported adverse events among Chinese healthcare workers immunized with COVID-19 vaccines composed of inactivated SARS-CoV-2.
Cheng Y; Li T; Zheng Y; Xu B; Bi Y; Hu Y; Zhou YH
Hum Vaccin Immunother; 2022 Nov; 18(5):2064134. PubMed ID: 35452357
[TBL] [Abstract][Full Text] [Related]
30. Pattern of self-reported adverse events related to COVID-19 vaccines in Saudi Arabia: A nationwide study.
Alkhalifah JM; Al Seraihi A; Al-Tawfiq JA; Alshehri BF; Alhaluli AH; Alsulais NM; Alessa MM; Seddiq W; Aljeri T; Qahtani MH; Barry M; Al-Otaiby M
Front Public Health; 2023; 11():1043696. PubMed ID: 36908451
[TBL] [Abstract][Full Text] [Related]
31. Safety and side effect profile of Pfizer-BioNTech COVID-19 vaccination among healthcare workers: A tertiary hospital experience in Singapore.
Lim SM; Chan HC; Santosa A; Quek SC; Liu EHC; Somani J
Ann Acad Med Singap; 2021 Sep; 50(9):703-711. PubMed ID: 34625758
[TBL] [Abstract][Full Text] [Related]
32. Adverse events following immunisation of COVID-19 vaccine among health care workers in the first phase of vaccination.
Rahmat H; Leelavathi M; Wan Ismail WF
Med J Malaysia; 2022 Nov; 77(6):637-642. PubMed ID: 36448378
[TBL] [Abstract][Full Text] [Related]
33. Adverse events of six COVID-19 vaccines in patients with autoimmune rheumatic diseases: a cross-sectional study.
Esquivel-Valerio JA; Skinner-Taylor CM; Moreno-Arquieta IA; Cardenas-de la Garza JA; Garcia-Arellano G; Gonzalez-Garcia PL; Almaraz-Juarez FDR; Galarza-Delgado DA
Rheumatol Int; 2021 Dec; 41(12):2105-2108. PubMed ID: 34622311
[TBL] [Abstract][Full Text] [Related]
34. Reactogenicity and Immunogenicity of the ChAdOx1 nCOV-19 Coronavirus Disease 2019 Vaccine in South Korean Healthcare Workers.
Hyun J; Park Y; Song YG; Han SH; Park SY; Kim SH; Park JS; Jeon SY; Lee HS; Lee KH
Yonsei Med J; 2022 Dec; 63(12):1078-1087. PubMed ID: 36444543
[TBL] [Abstract][Full Text] [Related]
35. Adverse Events following AstraZeneca COVID-19 Vaccine in Saudi Arabia: A Cross-Sectional Study among Healthcare and Nonhealthcare Workers.
Alghamdi AA; Alkazemi A; Alissa A; Alghamdi I; Alwarafi G; Waggas HA
Intervirology; 2022; 65(2):104-109. PubMed ID: 34544075
[TBL] [Abstract][Full Text] [Related]
36. Safety and adverse effects of the coronavirus disease 2019 vaccine among the general Japanese adult population.
Lu X; Masuda S; Horlad H; Katoh T
Vaccine; 2023 Aug; 41(35):5090-5096. PubMed ID: 37455163
[TBL] [Abstract][Full Text] [Related]
37. Evaluate the side effect associated with COVID-19 vaccine on adolescents in Riyadh, Saudi Arabia: A cross-section study.
Aldali JA; Alotaibi FT; Alasiri GA; Almesned RA; Alromih AM; Almohandes AM; Alsenidi SF
Saudi Med J; 2022 Nov; 43(11):1248-1253. PubMed ID: 36379531
[TBL] [Abstract][Full Text] [Related]
38. Seroresponse to SARS-CoV-2 Vaccines among Maintenance Dialysis Patients over 6 Months.
Hsu CM; Weiner DE; Manley HJ; Aweh GN; Ladik V; Frament J; Miskulin D; Argyropoulos C; Abreo K; Chin A; Gladish R; Salman L; Johnson D; Lacson EK
Clin J Am Soc Nephrol; 2022 Mar; 17(3):403-413. PubMed ID: 35144972
[TBL] [Abstract][Full Text] [Related]
39. COVID-19 vaccine confidence and hesitancy among health care workers: A cross-sectional survey from a MERS-CoV experienced nation.
Barry M; Temsah MH; Alhuzaimi A; Alamro N; Al-Eyadhy A; Aljamaan F; Saddik B; Alhaboob A; Alsohime F; Alhasan K; Alrabiaah A; Alaraj A; Halwani R; Jamal A; Alsubaie S; Al-Shahrani FS; Memish ZA; Al-Tawfiq JA
PLoS One; 2021; 16(11):e0244415. PubMed ID: 34843462
[TBL] [Abstract][Full Text] [Related]
40. Tolerability of COVID-19 Infection and Messenger RNA Vaccination Among Patients With a History of Kawasaki Disease.
Beckley M; Olson AK; Portman MA
JAMA Netw Open; 2022 Aug; 5(8):e2226236. PubMed ID: 35960521
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
